# EDGAR Filing Document

**Accession Number:** 0001837344
**File Stem:** 0001213900-23-001715
**Filing Date:** 2023-1
**Character Count:** 69342
**Document Hash:** a95066a453664acc9b57d95c1f1750d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001715.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001213900-23-001715

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20221230

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nocturne Acquisition Corp
- **CENTRAL INDEX KEY:** 0001837344
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40259
- **FILM NUMBER:** 23518740

**BUSINESS ADDRESS:**
- **STREET 1:** 3 GERMAY DRIVE
- **STREET 2:** UNIT 4 #1066
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19804
- **BUSINESS PHONE:** 8582287142

**MAIL ADDRESS:**
- **STREET 1:** 3 GERMAY DRIVE
- **STREET 2:** UNIT 4 #1066
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19804

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **December 30, 2022**

**NOCTURNE ACQUISITION CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-40259** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification Number) |

---

**3 Germay Drive, Unit 4 #1066 Wilmington, DE 19804**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(858) 228-7142**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one ordinary share, $0.0001 par value and one right | MBTCU | The Nasdaq Stock Market LLC |
| Ordinary shares included as part of Units | MBTC | The Nasdaq Stock Market LLC |
| Rights included as part of the Units | MBTCR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure** 

This Current Report on Form 8-K (the "<u>Current Report</u>") is being filed solely to provide additional information regarding the agreements discussed in the Current Report on Form 8-K filed by Nocturne Acquisition Corporation, a special purpose acquisition company incorporated as a Cayman Islands exempted company ("<u>Nocturne</u>"), on January 4, 2023. Additional information regarding these agreements and the proposed initial business combination will be included in the registration statement on Form S-4 to be filed by Nocturne in connection with the proposed initial business combination (the "<u>Registration Statement</u>").

**Merger Agreement**

As previously announced, on December 30, 2022, Nocturne entered into an Agreement and Plan of Merger and Reorganization (the "<u>Merger Agreement</u>") with Nocturne Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nocturne ("<u>Merger Sub</u>"), and Cognos Therapeutics, Inc., a Delaware corporation ("<u>Cognos</u>").

Pursuant to the Merger Agreement, (i) Nocturne will domesticate as a Delaware corporation and de-register as a Cayman Islands exempted company (the "<u>Domestication</u>") and (ii) Merger Sub will merge with and into Cognos with Cognos continuing as the surviving entity and a wholly owned subsidiary of Nocturne (the "<u>Merger</u>" and together with the Domestication and the other transactions contemplated by the Merger Agreement, the "<u>Business Combination</u>"). In connection with the Domestication, Nocturne will change its name to "Cognos Therapeutics Holdings, Inc." We refer to Nocturne following the Business Combination as "<u>Cognos Therapeutics</u>."

As a result of the Domestication, each issued and outstanding ordinary share of Nocturne will be converted into an equal number of shares of common stock of Cognos Therapeutics, par value $0.0001 per share ("<u>Cognos Therapeutics Common Stock</u>"), and each right to receive ordinary shares of Nocturne (each, a "<u>Right</u>") will convert into the right to receive one-tenth (1/10) of one share of Cognos Therapeutics Common Stock. At the closing of the Business Combination, each Right will receive one-tenth (1/10) of one share of Cognos Therapeutics Common Stock.

In connection with the Business Combination, Nocturne's sponsor, Nocturne Sponsor, LLC (the "<u>Sponsor</u>"), agreed to forfeit certain equity securities of Nocturne owned by it (collectively, the "<u>Sponsor Shares</u>") under certain circumstances pursuant to the Sponsor Forfeiture Agreement, as further described below under "Sponsor Forfeiture Agreement."

***Conversion of Securities***

 ****

In consideration for the Merger, the current holders of shares of Cognos' common stock, par value $0.0001 per share ("<u>Cognos Common Stock</u>") will have their shares of Cognos Common Stock canceled and converted into the right to receive a certain number of shares of Cognos Therapeutics Common Stock (the "<u>Merger Consideration Shares</u>") as provided for in the Merger Agreement, such that, following the consummation of the Merger and the transactions contemplated thereby, the holders of Nocturne ordinary shares and Cognos Common Stock at the time of the consummation of the Merger (the "<u>Closing</u>") will constitute, collectively, the holders of Cognos Therapeutics Common Stock on a post-Closing basis. The aggregate number of Merger Consideration Shares will be based on a pre-money enterprise value of Cognos of $120,000,000 and a per-share valuation of Cognos Therapeutics Common Stock of $10.30, and will be subject to certain adjustments with respect to Cognos' net indebtedness and transaction expenses at Closing (as more fully provided in the Merger Agreement).

Subject to the terms and conditions of the Merger Agreement, (i) each Cognos warrant (including any portion thereof) issued and outstanding immediately prior to Closing will be assumed by Cognos Therapeutics and converted into a warrant for shares of Cognos Therapeutics Common Stock and (ii) each option to purchase Cognos Common Stock issued by Cognos, and outstanding immediately prior to Closing will be assumed by Cognos Therapeutics and converted into an option to purchase shares of Cognos Therapeutics Common Stock, in each case, on a post-Closing basis.

***Conditions to Closing***

The Merger Agreement is subject to the satisfaction or waiver of certain customary Closing conditions, including, among others, (i) that the Nocturne Cash on Hand (as defined in the Merger Agreement) shall not be less than $10,000,000, (ii) approval of the business combination and related agreements and transactions by the respective stockholders of Nocturne and Cognos, (iii) to the extent applicable, the consummation of the PIPE Investment and the Note Investment (as each is defined in the Merger Agreement), (iv) effectiveness of the Registration Statement, (v) expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, (vi) receipt of conditional approval for listing of the Cognos Therapeutics Common Stock on Nasdaq, (vii) that Cognos Therapeutics will have at least $5,000,001 of net tangible assets as of immediately after the Closing, (viii) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger, (ix) the Ancillary Agreements (as defined in the Merger Agreement) shall be in full force and effect and shall not have been rescinded by any of the parties thereto, and (x) certain directors and officers of Nocturne, as agreed between Nocturne and Cognos, shall have been removed from their respective positions or tendered their irrevocable resignations, effective as of the Closing.

***Covenants, Representations and Warranties***

The Merger Agreement contains various covenants, including, among others, covenants providing that (i) the parties must conduct their respective businesses in the ordinary course in all material respects through the Closing, (ii) the parties must not solicit or enter into any agreements with respect to potential alternative transactions to the Business Combination, subject to certain exceptions, (iii) Cognos must prepare and deliver to Nocturne certain annual and interim financial statements, (iv) Nocturne must file the Registration Statement and take certain other actions to obtain the requisite approval of the Nocturne stockholders of various proposals regarding the Business Combination, and (v) the parties must exercise their respective reasonable best efforts to obtain any necessary approvals from governmental agencies. The Merger Agreement also contains customary representations and warranties by Nocturne, Merger Sub and Cognos that do not survive the Closing.

***Termination***

The Merger Agreement may be terminated at any time prior to the Closing (i) by mutual written consent of Nocturne and Cognos, (ii) by Nocturne, if certain approvals of the stockholders of Cognos are not obtained within five business days after the Registration Statement has been declared effective by the U.S. Securities and Exchange Commission (the "<u>SEC</u>"), or (iii) by either Nocturne or Cognos in certain other circumstances set forth in the Merger Agreement including (a) if any applicable law is in effect making the Business Combination illegal or any final, non-appealable order is in effect permanently preventing the consummation of the Business Combination, (b) in the event of certain uncured breaches by the other party, (c) if the required vote is not obtained at the meeting of the Nocturne stockholders to approve the Business Combination, or (d) if the Closing has not occurred by September 30, 2023.

**Sponsor Forfeiture Agreement**

 ****

Concurrently with the execution of the Merger Agreement, Nocturne entered into a letter agreement (the "<u>Sponsor Forfeiture Agreement</u>") with the Sponsor and Cognos.

Pursuant to the Sponsor Forfeiture Agreement, the Sponsor agreed that if the Nocturne Cash on Hand is less than the Minimum Cash Amount (as defined in the Merger Agreement), and Cognos, in its sole discretion, elects to waive compliance with the Closing condition under the Merger Agreement that the Nocturne Cash on Hand shall not be less than the Minimum Cash Amount and to proceed with the Closing, then at (and contingent upon) the Closing, Sponsor shall irrevocably forfeit and surrender to Nocturne the Sponsor Shares in the following form and substance: Sponsor shall (a) keep 2,963,000 shares (87.5% of Sponsor Shares) and forfeit the rest if the Nocturne Cash on Hand is less than the Minimum Cash Amount but equals or exceeds $7,500,000, (b) keep 2,539,000 shares (75% of Sponsor Shares) and forfeit the rest if the Nocturne Cash on Hand is less than $7,500,000 but equals or exceeds $5,000,000 and (c) keep 1,693,000 shares (50% of Sponsor Shares) and forfeit the rest if there is no Nocturne Cash on Hand. The number of Sponsor Shares kept and forfeited shall be pro-rated to the extent that the Nocturne Cash on Hand falls between any of the amounts in clauses (a) through (c) above.

**Company Support Agreement** 

Concurrently with the execution of the Merger Agreement, Nocturne also entered into a transaction support agreement (the "<u>Cognos Support Agreement</u>") with Cognos and certain stockholders of Cognos. Under the Cognos Support Agreement, such Cognos stockholders agreed to appear and vote certain securities of Cognos set forth in the Cognos Support Agreement in favor of adopting the Merger Agreement and approving the related transactions (or deliver a written consent to such effect). The securities of Cognos owned by its stockholders who are party to the Cognos Support Agreement and subject to such agreement are sufficient to approve the adoption of the Merger Agreement.

The foregoing description of the Merger Agreement, the Sponsor Forfeiture Agreement, the Cognos Support Agreement and the transactions and documents contemplated thereby is not complete and is subject to and qualified in its entirety by reference to the Merger Agreement, Form of Sponsor Forfeiture Agreement and Form of Cognos Support Agreement, copies of which are filed with this Current Report as Exhibit 2.1, Exhibit 10.2 and Exhibit 10.3, respectively, and the terms of which are incorporated by reference herein.

The Merger Agreement, Form of Sponsor Forfeiture Agreement and Form of Cognos Support Agreement have been filed herewith to provide investors with information regarding their terms. They are not intended to provide any other factual information about Nocturne, Cognos or their respective affiliates. The representations, warranties, covenants and agreements contained in the Merger Agreement, Form of Sponsor Forfeiture Agreement, Form of Cognos Support Agreement and the other documents related thereto were made only for purposes of the Merger Agreement as of the specific dates therein, were solely for the benefit of the parties to such agreements, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to such agreements instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Merger Agreement, Form of Sponsor Forfeiture Agreement, or Form of Cognos Support Agreement and should not rely on the representations, warranties, covenants and agreements or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Merger Agreement, Form of Sponsor Forfeiture Agreement and Form of Cognos Support Agreement, as applicable, which subsequent information may or may not be fully reflected in Nocturne's public disclosures.

**Forward-Looking Statements** 

This Current Report on Form 8-K contains certain "forward-looking statements" within the meaning of the Securities Act and the Exchange Act. Statements that are not historical facts, including statements about the pending Merger between Nocturne and Cognos and the transactions contemplated thereby, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated cash available at Closing; the anticipated use of the combined company's cash and cash equivalents; the benefits of the proposed transaction; integration plans; the combined company's projected financial information and anticipated future financial condition and results of operations; Cognos' business strategy, commercial operating plans, product development plans; and the expected timing of the transactions related to the Business Combination. The words "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

These forward-looking statements are subject to a number of risks and uncertainties, including the risks that: Cognos, an early stage company, may not become profitable for many years; potential customers may withdraw from negotiations and indications of interest with Cognos; Cognos may fail to manage growth effectively; Cognos' indebtedness could increase its vulnerability to adverse economic and industry conditions, limit its ability to obtain additional financing, require the dedication of a substantial portion of its cash flow from operations to service its indebtedness, limit its flexibility in planning for, or reacting to, changes in its business and place Cognos at a competitive disadvantage; Cognos may not be able to secure government approvals and authorizations for its products; there may not be a viable market for Cognos' products; Cognos may fail to gain market share from its competitors; there could be a decrease in the availability or an increase in the price of raw materials needed by Cognos in the production of its products; changes in federal, state and local government laws, regulations and policies could have a negative impact on Cognos; Cognos may be unable to fund and make investments in developing intellectual property and other proprietary information to improve and scale its products; Cognos may have to defend against claims of intellectual property infringement; Cognos' information technology systems may fail as Cognos' business grows; Cognos may fail to retain key personnel or attract additional highly skilled employees; Cognos and Nocturne may be unable to successfully or timely consummate the Business Combination, including as a result of any regulatory approvals that are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Business Combination or if approval by the stockholders of Cognos or Nocturne is not obtained; and the Business Combination may not result in the anticipated benefits; as well as the risks discussed in Nocturne's final prospectus dated March 30, 2021 under the heading "Risk Factors," and other documents Nocturne has filed, or will file, with the SEC, including the Registration Statement (which will include a proxy statement/prospectus). These risks and uncertainties may be amplified by the ongoing COVID-19 pandemic, which has caused and may continue to cause significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Nocturne nor Cognos presently know, or that Cognos or Nocturne currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Nocturne's and Cognos' expectations, plans, or forecasts of future events and views as of the date of this Current Report on Form 8-K. Nocturne and Cognos anticipate that subsequent events and developments will cause Nocturne's and Cognos' assessments to change. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Nocturne, Cognos and their affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

**Additional Information and Where to Find It** 

A full description of the terms of the Merger Agreement, including the Domestication and the Merger, will be provided in the Registration Statement to be filed by Nocturne with the SEC, which will include a prospectus with respect to the combined company's securities to be issued in connection with the Merger and a proxy statement with respect to the stockholder meeting of Nocturne to vote on the Merger. **Nocturne urges its investors, stockholders and other interested persons to read, when available, the Registration Statement as well as other documents filed with the SEC because these documents will contain important information about Nocturne, Cognos and the Business Combination.** After the Registration Statement is declared effective, the definitive proxy statement/prospectus to be included in the Registration Statement will be mailed to stockholders of Nocturne as of a record date to be established for voting on the proposed Merger. Once available, stockholders will also be able to obtain a copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to Nocturne Acquisition Corporation, 3 Germay Drive, Unit 4 #1066 Wilmington, DE, 19804, Attention Thomas Ao. The preliminary and definitive proxy statement/prospectus to be included in the Registration Statement, once available, can also be obtained, without charge, at the SEC's website (www.sec.gov).

**Participants in Solicitation** 

Nocturne, Cognos and their respective directors and officers may be deemed to be participants in the solicitation of proxies from Nocturne's stockholders in connection with the proposed business combination. Information about Nocturne's directors and executive officers and their ownership of Nocturne's securities is set forth in Nocturne's filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed business combination may be obtained by reading the Registration Statement when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

**Safe Harbor Statement** 

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Nocturne, the combined company or Cognos, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits. The following exhibits are filed with this Form 8-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibits** |
| 2.1 | [Agreement and Plan of Merger, dated as of December 30, 2022 (incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed with the Commission on January 4, 2023).\*](http://www.sec.gov/Archives/edgar/data/1837344/000121390023000635/ea171121ex2-1_nocturne.htm) |
| 10.2 | [Form of Sponsor Forfeiture Agreement.](ea171343ex10-2_nocturne.htm) |
| 10.3 | [Form of Cognos Support Agreement. \*](ea171343ex10-3_nocturne.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

\* Exhibits and schedules have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K and will be furnished to the Securities and Exchange Commission upon request.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** |
| By: | /s/ Henry Monzon | /s/ Henry Monzon |
|  | Name: | Henry Monzon |
|  | Title: | Chairman and Chief Executive Officer |

---

Dated: January 9, 2023

## Exhibit 10.2

**Exhibit 10.2**

EXECUTION VERSION

**<u>SPONSOR FORFEITURE AGREEMENT</u>**

December 30, 2022

Nocturne Acquisition Corporation

3 Germay Drive

Wilmington, DE 19804

Cognos Therapeutics, Inc.

10604 S La Cienega Blvd.

Inglewood, CA 90304

**Re: <u>Forfeiture of Sponsor Shares</u>**

Ladies and Gentlemen:

Reference is made to that certain Agreement and Plan of Merger and Reorganization dated as of the date hereof (as amended from time to time in accordance with its terms, the "***Merger Agreement***"), dated as of the date hereof, by and among Nocturne Acquisition Corporation, a Cayman Islands exempted company listed on the Nasdaq Stock Market (which shall transfer by way of continuation to and domesticate as a Delaware corporation prior to the Closing (as defined in the Merger Agreement)) ("***Nocturne***"), Nocturne Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Nocturne, and Cognos Therapeutics, Inc., a Delaware corporation (the "***Company***"). Capitalized terms used herein, but not defined herein, shall have the meanings ascribed to them in the Merger Agreement.

In order to induce the Company and Nocturne to enter into the Merger Agreement and to proceed with the Merger and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Nocturne Sponsor, LLC, a Delaware limited liability company and Nocturne's sponsor (the "***Sponsor***"), and Nocturne hereby agree, pursuant to this letter agreement (this "***Letter Agreement***"), for the benefit of the Company, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. If the Nocturne Cash on Hand is less than the Minimum Cash Amount, and the Company, in its sole discretion, elects to waive compliance with the Closing condition under the Merger Agreement that the Nocturne Cash on Hand shall not be less than the Minimum Cash Amount, and to proceed with the Closing, then at (and contingent upon) the Closing, Sponsor shall irrevocably forfeit and surrender to Nocturne the Founder Shares and private placement units in the form and substance set forth in this section (the "  ***Forfeiture*** "): Sponsor shall (a) keep 2,963,000 shares (eighty-seven and one-half percent (87.5%) of Sponsor Shares) and forfeit the rest if Nocturne Cash on Hand is less than the Minimum Cash Amount but equals or exceeds $7,500,000, (b) keep 2,539,000 shares (seventy-five percent (75%) of Sponsor Shares) and forfeit the rest if Nocturne Cash on Hand is less than $7,500,000 but equals or exceeds $5,000,000 and (c) keep 1,693,000 shares (fifty percent (50%) of Sponsor Shares) and forfeit the rest if there is no Nocturne Cash on Hand. The number of Sponsor Shares kept and forfeited shall be pro-rated to the extent that the Nocturne Cash on Hand falls between any of the amounts in clauses (a) through (c) above. The number of Sponsor Shares forfeited shall, to the extent applicable, be rounded up to the next greater whole number. The amount of forfeited Sponsor Shares shall be subject to equitable adjustment for any stock dividend, subdivision, reclassification, recapitalization, split, combination, consolidation or exchange of shares, or any similar event occurring prior to the Closing.

2. To effect the Forfeiture, the Sponsor shall transfer the forfeited Sponsor Shares, if any, to Nocturne for cancellation and in exchange for no consideration. Nocturne shall immediately retire and cancel all of the forfeited Sponsor Shares and shall direct Nocturne's transfer agent (or such other intermediaries as appropriate) to take any and all such actions incident thereto. The Sponsor and Nocturne each shall (a) take such actions as are necessary to cause the forfeited Sponsor Shares to be retired and canceled, after which time such forfeited Sponsor Shares shall no longer be issued or outstanding, and (b) provide the Company with evidence that such retirement and cancellation has occurred.

&nbsp;&nbsp;&nbsp;&nbsp;3. Prior to the Closing, the Sponsor shall not, directly or indirectly, transfer or otherwise dispose of the Sponsor Shares other than pursuant to the Forfeiture.

4. The Sponsor hereby
 represents and warrants to the Company, as of the date hereof and as of immediately prior to the Closing, that the Sponsor owns, and
 holds of record, all of the Sponsor Shares, free and clear of all Liens and other obligations in respect of such Sponsor
 Shares.

5. This Letter Agreement (together with, as between the Company and Nocturne, the Merger Agreement) constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof. This Letter Agreement may not be changed, amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.

6. No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of each of the other parties hereto. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor and Nocturne and their respective successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;7. The Law of the State of New York shall govern (a) all claims or matters related to or arising from this Agreement (including any tort or non-contractual claims) and the negotiation, execution or performance of this Letter Agreement or any of the transactions contemplated hereby and (b) any questions concerning the construction, interpretation, validity and enforceability of this Letter Agreement, and the performance of the obligations imposed by this Agreement, in each case without giving effect to any choice-of-law or conflict-of-law rules or provisions (whether of the State of New York or any other jurisdiction) that would cause the application of the Law of any jurisdiction other than the State of New York. EACH PARTY TO THIS LETTER AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES HERETO (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS LETTER AGREEMENT, THE TRANSACTIONS OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES UNDER THIS AGREEMENT. EACH PARTY HERETO FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. Each party hereto submits to the exclusive jurisdiction of any court of the State of New York sitting in New York County or, if it has or can obtain jurisdiction, the Federal District Court for the Southern District of New York, in any Proceeding arising out of or relating to this Letter Agreement or the negotiation, execution or performance of this Letter Agreement or any of the transactions contemplated hereby, agrees that all claims in respect of the Proceeding shall be heard and determined in any such court and agrees not to bring any Proceeding arising out of or relating to this Letter Agreement in any other courts. Nothing in this paragraph, however, shall affect the right of any party hereto to serve legal process in any other manner permitted by Law or at equity. Each party hereto agrees that a final judgment in any Proceeding so brought shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by Law or at equity.

&nbsp;&nbsp;&nbsp;&nbsp;8. Each party hereto acknowledges that the rights of each party to consummate the transactions contemplated hereby are unique, recognizes and affirms that in the event of a breach of this Letter Agreement by any party hereto, money damages may be inadequate and the non-breaching parties may have not adequate remedy at Law, and agree that irreparable damage would occur in the event that any of the provisions of this Letter Agreement were not performed by an applicable party in accordance with their specific terms or were otherwise breached. Accordingly, each party shall be entitled to seek an injunction or restraining order to prevent breaches of this Letter Agreement and to seek to enforce specifically the terms and provisions hereof, without the requirement to post any bond or other security or to prove that money damages would be inadequate, this being in addition to any other right or remedy to which such party may be entitled under this Letter Agreement, at Law or in equity.

9. This Letter Agreement shall immediately terminate, without any further action by the parties hereto, at such time, if any, that the Merger Agreement is terminated in accordance with its terms.

10. This Letter Agreement may be executed and delivered in one or more counterparts and by fax, email or other electronic transmission, each of which shall be deemed an original and all of which shall be considered one and the same agreement.

**[Signature page follows]**

---

| | | |
|:---|:---|:---|
| Sincerely, | Sincerely, | Sincerely, |
| **NOCTURNE SPONSOR, LLC** | **NOCTURNE SPONSOR, LLC** | **NOCTURNE SPONSOR, LLC** |
| By: MINDFULNESS SPONSOR COMPANY | By: MINDFULNESS SPONSOR COMPANY | By: MINDFULNESS SPONSOR COMPANY |
| LIMITED, its Managing Member | LIMITED, its Managing Member | LIMITED, its Managing Member |
| By: | /s/ Ka Seng (Thomas) Ao | /s/ Ka Seng (Thomas) Ao |
|  | Name: | Ka Seng (Thomas) Ao |
|  | Title: | Director |
| **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** |
| By: | /s/ Henry Monzon | /s/ Henry Monzon |
|  | Name: | Henry Monzon |
|  | Title: | Chief Executive Officer |

---

[*Signature Page to Sponsor Forfeiture Agreement*]

Acknowledged and Agreed:

COGNOS THERAPEUTICS, INC.

---

| | | |
|:---|:---|:---|
| By: | /s/ Frank Adell | /s/ Frank Adell |
|  | Name:  | Frank Adell |
|  | Title: | Chief Executive Officer |

---

[*Signature Page to Sponsor Forfeiture Agreement*]

## Exhibit 10.3

**Exhibit 10.3**

**STOCKHOLDER SUPPORT AGREEMENT**

This STOCKHOLDER SUPPORT AGREEMENT (this "<u>Agreement</u>") is dated as of December 30, 2022, by and among Nocturne Acquisition Corporation, a Cayman Islands exempted company ("<u>Nocturne</u>"), the Persons set forth on <u>Schedule I</u> hereto (each, a "<u>Stockholder</u>" and, collectively, the "<u>Stockholders</u>"), and Cognos Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

**RECITALS**

WHEREAS, on December 30, 2022, Nocturne, Nocturne Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Nocturne ("<u>Merger Sub</u>"), and the Company entered into an Agreement and Plan of Merger and Reorganization (as amended or modified from time to time, the "<u>Merger Agreement</u>"), pursuant to which, among other transactions, upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into the Company (the "<u>Merger</u>"), with the Company surviving the Merger as a wholly owned subsidiary of Nocturne, and each Company Share issued and outstanding as of immediately prior to the Effective Time will, in each case, be cancelled and automatically converted into the right to receive a certain number of shares of Nocturne Common Stock as described in the Merger Agreement (such transaction, the Merger and the other transactions contemplated by the Merger Agreement, the "<u>Transactions</u>");

WHEREAS, as of the date hereof, the Stockholders are the holders of record and "beneficial owners" (within the meaning of Rule 13d-3 of the Exchange Act) of, and have sole voting power over, such number of Company Shares as are indicated opposite each of their names on <u>Schedule I</u> attached hereto (all such Company Shares, together with any Company Shares of which ownership of record or the power to vote (including, without limitation, by proxy or power of attorney) is hereafter acquired by any such Stockholder during the period from the date hereof through the Expiration Time (as defined below), including by purchase, as a result of a stock dividend, stock split, recapitalization, combination, reclassification, exchange or change of such shares, or upon exercise or conversion of any securities, are referred to herein as the "<u>Subject Shares</u>"); and

WHEREAS, as an inducement to Nocturne and the Company to enter into the Merger Agreement and to consummate the Transactions, the parties hereto desire to agree to certain matters as set forth herein.

**AGREEMENT**

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as follows:

**ARTICLE 1**

**STOCKHOLDER SUPPORT AGREEMENT; COVENANTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Binding Effect of the Merger Agreement</u>. Each Stockholder hereby acknowledges that it has read the Merger Agreement and this Agreement and has had the opportunity to consult with its tax and legal advisors. Each Stockholder shall be bound by and comply with Section 6.8 (*Communications; Press Releases*) of the Merger Agreement (and any relevant definitions contained in such Section) as if (a) such Stockholder was an original signatory to the Merger Agreement with respect to such provision, and (b) each reference to the Company contained in Section 6.8 of the Merger Agreement (other than the first clause of the first sentence of Section 6.8) also referred to each such Stockholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Transfer of Shares</u>. During the period commencing on the date hereof and ending on the earlier to occur of (a) the Effective Time, and (b) such date and time as the Merger Agreement shall be terminated in accordance with Section 7.1 of the Merger Agreement (the "<u>Expiration Time</u>"), each Stockholder, severally and not jointly, agrees that it shall not (i) sell, assign, offer, exchange, transfer (including by operation of law), pledge, dispose of, permit to exist any material lien with respect to, or otherwise encumber any of the Subject Shares or otherwise agree or commit to do any of the foregoing, except for a sale, assignment or transfer pursuant to the Merger Agreement or to another stockholder of the Company that is a party to this Agreement and bound by the terms and obligations hereof, (ii) deposit any Subject Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement, or (iii) enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law) or other disposition of any Subject Shares; <u>provided</u>, that the foregoing shall not prohibit the transfer of the Subject Shares (A) if Stockholder is an individual (1) to any member of such Stockholder's immediate family, or to a trust for the benefit of Stockholder or any member of Stockholder's immediate family, the sole trustees of which are such Stockholder or any member of such Stockholder's immediate family or (2) by will, other testamentary document, under the laws of intestacy or by virtue of laws of descent and distribution upon the death of Stockholder; or (B) if Stockholder is an entity, to a partner, member, or affiliate of Stockholder, but only if, in the case of clause (A) and (B), such transferee shall concurrently execute this Agreement or a joinder agreeing to become a party to this Agreement. Any attempted transfer of Subject Shares or any interest therein in violation of this <u>Section 1.2</u> shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>New Shares</u>. In the event that, during the period commencing on the date hereof and ending at the Expiration Time, (a) any Subject Shares are issued to a Stockholder after the date of this Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification, combination or exchange of Subject Shares or otherwise, (b) a Stockholder purchases or otherwise acquires beneficial ownership of any Subject Shares or (c) a Stockholder acquires the right to vote or share in the voting of any Subject Shares (collectively the "<u>New Securities</u>"), then such New Securities acquired or purchased by such Stockholder shall be subject to the terms of this Agreement to the same extent as if they constituted the Subject Shares owned by such Stockholder as of the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <u>Agreement to Vote</u>. During the period commencing on the date hereof until the Expiration Time, each Stockholder, with respect to its, his or her Subject Shares, severally and not jointly, unconditionally and irrevocably agrees that, at any meeting of the stockholders of the Company (or any adjournment or postponement thereof), and in any action by written consent of the stockholders of the Company requested by the Company Board (which written consent shall be delivered promptly, and in any event within two (2) Business Days, after (x) the Registration Statement has been declared effective, and (y) the Company requests such delivery), such Stockholder shall, if a meeting is held, appear at the meeting, in person or by proxy, or otherwise cause its, his or her Subject Shares to be counted as present thereat for purposes of establishing a quorum, and such Stockholder shall vote or provide consent (or cause to be voted or consented), in person or by proxy, all of its, his or her Subject Shares:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) to approve and adopt the Merger Agreement and the Transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) in any other circumstances upon which a consent or other approval is required under the Company Governing Documents or otherwise sought with respect to, or in connection with, the Merger Agreement or the Transactions, to vote, consent or approve (or cause to be voted, consented or approved) all of such Stockholder's Subject Shares held at such time in favor thereof; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) against any Competing Transaction or any proposal, action or agreement that would impede, frustrate, prevent or nullify any provision of this Agreement, the Merger Agreement or the Merger.

Each Stockholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. Notwithstanding the foregoing, such Stockholder shall not vote or provide consent with respect to any of its, his or her Subject Shares to the extent Stockholder is not a director, officer or affiliate of the Company or holder of Subject Shares representing greater than 5% of the outstanding shares of capital stock of the Company, or take any other action, in each case to the extent any such vote, consent or other action would preclude Nocturne from filing with the SEC the Registration Statement on Form S-4 as contemplated by the Merger Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <u>No Challenges</u>. Each Stockholder agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Nocturne, Merger Sub, the Company or any of their respective successors or directors (a) challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement, (b) alleging a breach of any fiduciary duty of any person in connection with the evaluation, negotiation or entry into the Merger Agreement or (c) otherwise relating to the negotiation, execution or delivery of this Agreement, the Merger Agreement or the consummation of the transactions contemplated hereby and thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <u>Reserved</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <u>Investor Rights Agreement</u>. Each of the Stockholders set forth on <u>Schedule II</u> (and any Person to whom each such Stockholder transfers its Subject Shares) will deliver, substantially simultaneously with the Effective Time, a duly executed copy of the Investor Rights Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <u>Lock-up Agreements</u>. Each of the Stockholders set forth on <u>Schedule III</u> (and any Person to whom each such Stockholder transfers its Subject Shares) will deliver, prior to the Closing, a duly executed copy of the Lock-up Agreement effective as of the Effective Time, substantially in the form attached as Exhibit A to the Merger Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <u>Appraisal and Dissenters' Rights</u>. Each Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert or perfect, any rights of appraisal or other similar rights to dissent (including any notice requirements related thereto) with respect to the Merger, the Merger Agreement or any of the Transactions that Stockholder may have by virtue of ownership of Subject Shares (including all rights under Section 262 of the DGCL).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 <u>Exclusivity</u>. Unless this Agreement shall have been terminated in accordance with <u>Section 3.1</u>, each Stockholder, severally and not jointly, agrees not to, and shall not authorize or permit any of its, his or her Related Parties to, directly or indirectly, (a) solicit or take any action to facilitate or encourage any inquiries or the making, submission or announcement of, any proposal or offer from any Competing Buyer that may constitute, or would reasonably be expected to lead to, a Competing Transaction; (b) enter into, participate in, continue or otherwise engage in, any discussions or negotiations with any Competing Buyer regarding a Competing Transaction; or (c) furnish (including through the Data Room) any information relating to the Company or any of its assets or businesses, or afford access to the assets, business, properties, books or records of the Company to a Competing Buyer, in all cases for the purpose of assisting with or facilitating, or that would otherwise reasonably be expected to lead to, a Competing Transaction; (d) approve, endorse or recommend any Competing Transaction; or (e) enter into a Competing Transaction or any agreement, arrangement or understanding (including any letter of intent or term sheet) relating to a Competing Transaction or publicly announce an intention to do so. Each Stockholder shall, and shall cause its, his or her Related Parties to, immediately cease any and all existing discussions or negotiations with any Person (other than the other party to the Merger Agreement and its Representatives) conducted prior to the date of this Agreement, or which is reasonably likely to give rise to or result in, a Competing Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <u>Consent to Disclosure</u>. To the extent required by law or regulation, each Stockholder hereby consents to the publication and disclosure in the Registration Statement (and, as and to the extent otherwise required by applicable securities Laws or the SEC or any other securities authorities, any other documents or communications provided by the Company or Nocturne to any Governmental Entity or to securityholders of Nocturne) of such Stockholder's identity and beneficial ownership of its Subject Shares and the nature of such Stockholder's commitments, arrangements and understandings under and relating to this Agreement and, if deemed appropriate by the Company or Nocturne, a copy of this Agreement. Each Stockholder will promptly provide any information reasonably requested by the Company or Nocturne in connection with the first sentence of this <u>Section 1.10</u> or as required by the SEC or any regulatory authority for any regulatory application or filing made or approval sought in connection with the Transactions (including filings with the SEC).

**ARTICLE 2**

**REPRESENTATIONS AND WARRANTIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Representations and Warranties of the Stockholders</u>. Each Stockholder represents and warrants as of the date hereof to Nocturne and the Company (solely with respect to itself, himself or herself and not with respect to any other Stockholder) as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Organization; Due Authorization</u>. If such Stockholder is not an individual, it is duly organized, validly existing and in good standing under the Laws of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within such Stockholder's corporate, limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such Stockholder. If such Stockholder is an individual, such Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and to perform his or her obligations hereunder. This Agreement has been duly executed and delivered by such Stockholder and, assuming due authorization, execution and delivery by the other parties to this Agreement, this Agreement constitutes a legally valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with the terms hereof (except as enforceability may be limited by bankruptcy Laws, other similar Laws affecting creditors' rights and general principles of equity affecting the availability of specific performance and other equitable remedies). If this Agreement is being executed in a representative or fiduciary capacity, the Person signing this Agreement has full power and authority to enter into this Agreement on behalf of the applicable Stockholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Ownership</u>. Such Stockholder is the record and beneficial owner (as defined in the Securities Act) of, and has good, valid and marketable title to, all of such Stockholder's Subject Shares, and there exist no Liens or any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such Subject Shares) affecting any such Subject Shares, other than Liens pursuant to (i) this Agreement, (ii) the Company Governing Documents, (iii) the Merger Agreement, (iv) the Ancillary Agreements (as applicable), or (v) any applicable securities Laws. Such Stockholder's Subject Shares are the only Company Shares or other voting equity securities in the Company owned of record or beneficially by such Stockholder on the date of this Agreement, and none of such Stockholder's Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of such Subject Shares, except as provided hereunder and under the applicable Ancillary Agreements. Such Stockholder has full voting power, full power of disposition and full power to issue instructions with respect to the matters set forth herein, and full power to agree to all of the matters applicable to such Stockholder set forth in this Agreement, in each case, with respect to such Stockholder's Subject Shares. Such Stockholder has not granted a proxy or power of attorney with respect to any of the Stockholder's Subject Shares that is inconsistent with the Stockholder's obligations pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>No Conflicts</u>. The execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder of his, her or its obligations hereunder will not, (i) if such Stockholder is not an individual, conflict with or result in a violation of the organizational documents of such Stockholder or (ii) require any consent, authorization or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon such Stockholder or such Stockholder's Subject Shares), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such Stockholder of its, his or her obligations under this Agreement, (iii) conflict with or violate any Law, or (iv) result in any material breach of or constitute a material default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien on any of the Subject Shares owned by such Stockholder pursuant to any Contract to which such Stockholder is a party or by which such Stockholder is bound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Litigation</u>. There are no Proceedings pending against such Stockholder, or to the knowledge of such Stockholder threatened against such Stockholder, before (or, in the case of threatened Proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such Stockholder of its, his or her obligations under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Adequate Information</u>. Such Stockholder is a sophisticated stockholder and has adequate information concerning the business and financial condition of Nocturne and the Company to make an informed decision regarding this Agreement and the transactions contemplated hereby and has independently and without reliance upon Nocturne or the Company and based on such information as such Stockholder has deemed appropriate, made its, his or her own analysis and decision to enter into this Agreement. Such Stockholder acknowledges that Nocturne and the Company have not made and do not make any representation or warranty, whether express or implied, of any kind or character except as expressly set forth in this Agreement. Such Stockholder acknowledges that the agreements contained herein with respect to the Subject Shares held by such Stockholder are irrevocable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Acknowledgment</u>. Such Stockholder understands and acknowledges that each of Nocturne and the Company is entering into the Merger Agreement in reliance upon such Stockholder's execution and delivery of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Brokerage Fees</u>. Other than as set forth on Section 3.15 of the Company Disclosure Letter no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders' fee or other commission in connection with the transactions contemplated by the Merger Agreement based upon arrangements made by such Stockholder, for which Nocturne, the Company or any of their affiliates may become liable following the Closing.

**ARTICLE 3<br>MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Termination</u>. This Agreement and all of its provisions shall automatically terminate upon the earliest of (a) the Expiration Time and (b) as to each Stockholder, the written agreement of Nocturne, the Company and such Stockholder. Upon such termination of this Agreement, all obligations of the parties under this Agreement will terminate, without any liability or other obligation on the part of any party hereto to any Person in respect hereof or the transactions contemplated hereby, and no party hereto shall have any claim against another (and no person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; <u>provided</u>, <u>however</u>, that the termination of this Agreement shall not relieve any party hereto from liability arising in respect of any breach of this Agreement prior to such termination. This <u>Article III</u> shall survive the termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Governing Law; Waiver of Jury Trial, Jurisdiction</u>. The Law of the State of New York shall govern (a) all claims or matters related to or arising from this Agreement (including any tort or non-contractual claims) and the negotiation, execution or performance of this Agreement or any of the transactions contemplated hereby and (b) any questions concerning the construction, interpretation, validity and enforceability of this Agreement, and the performance of the obligations imposed by this Agreement, in each case without giving effect to any choice-of-law or conflict-of-law rules or provisions (whether of the State of New York or any other jurisdiction) that would cause the application of the Law of any jurisdiction other than the State of New York. EACH PARTY TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS AGREEMENT, THE TRANSACTIONS OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES UNDER THIS AGREEMENT. EACH PARTY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. Each party submits to the exclusive jurisdiction of any court of the State of New York sitting in New York County or, if it has or can obtain jurisdiction, the Federal District Court for the Southern District of New York, in any Proceeding arising out of or relating to this Agreement or the negotiation, execution or performance of this Agreement or any of the transactions contemplated hereby, agrees that all claims in respect of the Proceeding shall be heard and determined in any such court and agrees not to bring any Proceeding arising out of or relating to this Agreement in any other courts. Nothing in this Section 3.2, however, shall affect the right of any party to serve legal process in any other manner permitted by Law or at equity. Each party agrees that a final judgment in any Proceeding so brought shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by Law or at equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Assignment</u>. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties and their respective successors and assigns; <u>provided</u> that neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned or delegated by any party (including by operation of Law) without the prior written consent of the other parties. Any assignment in violation of this Section 3.3 shall be void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <u>Specific Performance</u>. The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that (i) the parties hereto shall be entitled to seek an injunction or injunctions or other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, including the Stockholder's obligations to vote its Subject Shares as provided in this Agreement, without proof of damages, in any state or federal court within the State of New York, this being in addition to any other remedy to which such party is entitled under this Agreement or otherwise at law or in equity, and (ii) the right of specific performance is an integral part of the transactions contemplated by this Agreement and without that right, none of the parties would have entered into this Agreement. Each party agrees that it will not oppose the granting of specific performance and other equitable relief on the basis that the other parties have an adequate remedy at Law or that an award of specific performance is not an appropriate remedy for any reason at Law or equity. The parties acknowledge and agree that any party seeking an injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 3.4 shall not be required to provide any bond or other security in connection with any such injunction or to prove the inadequacy of money damages as a remedy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <u>Amendment; Waiver</u>. This Agreement may not be amended, changed, supplemented, waived or otherwise modified or terminated, except upon the execution and delivery of a written agreement executed by Nocturne, the Company and the Stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <u>Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement or the application of any such provision to any Person or circumstance shall be held to be prohibited by or invalid, illegal or unenforceable under applicable Law in any respect by a court of competent jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity, illegality or unenforceability, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <u>Notices</u>. All notices, demands and other communications to be given or delivered under this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered (or, if delivery is refused, upon presentment) or received by email prior to 6:00 p.m. eastern time on a Business Day and, if otherwise, on the next Business Day, (b) one (1) Business Day following sending by reputable overnight express courier (charges prepaid) or (c) three (3) days following mailing by certified or registered mail, postage prepaid and return receipt requested. Unless another address is specified in writing pursuant to the provisions of this paragraph, notices, demands and other communications to the parties shall be sent to the addresses indicated below:

<u>If to Nocturne</u>:

Nocturne Acquisition Corporation<br> 7244 Carrizo Drive

La Jolla, CA 92037,<br> Attention: Thomas Ao<br> Email: thomas@nocturnecorp.com

with a copy (which shall not constitute notice) to:

Dechert<br> 31/F Jardine House, One Connaught Place<br> Central, Hong Kong<br> Attention: Yang Wang<br> E-mail: yang.wang@dechert.com

<u>If to the Company</u>:

Cognos Therapeutics, Inc.<br> 10604 S La Cienega Blvd<br> Inglewood, CA 90304<br> Attention: Frank Adell<br> E-mail: frank.adell@cognosthx.com

with a copy (which shall not constitute notice) to:

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, 11th Floor

New York, New York, 10105

Telephone No.: (212) 370-1300<br> Attention: Barry I. Grossman, Esq.

E-mail: bigrossman@egsllp.com

<u>If to a Stockholder</u>:

To such Stockholder's address set forth on its signature page hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <u>Further Assurances</u>. Each Stockholder shall execute and deliver, or cause to be delivered, such additional documents, and take, or cause to be taken, all such further actions and do, or cause to be done, all things reasonably necessary (including under applicable Laws), or reasonably requested by Nocturne or the Company, to effect the actions and consummate the Merger and the other transactions contemplated by this Agreement and the Merger Agreement (including the Transactions), in each case, on the terms and subject to the conditions set forth therein and herein, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <u>Counterparts</u>. This Agreement may be executed in two or more counterparts (any of which may be delivered by electronic transmission), each of which shall constitute an original, and all of which taken together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <u>Entire Agreement</u>. This Agreement and the agreements referenced herein constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by or among the parties hereto to the extent they relate in any way to the subject matter hereof.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** | **NOCTURNE ACQUISITION CORPORATION** |
| By: | /s/ Henry Monzon | /s/ Henry Monzon |
|  | Name: | Henry Monzon |
|  | Title: | Chief Executive Officer |

---

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **COGNOS THERAPEUTICS, INC.** | **COGNOS THERAPEUTICS, INC.** | **COGNOS THERAPEUTICS, INC.** |
| By: | /s/ Frank Adell | /s/ Frank Adell |
|  | Name: | Frank Adell |
|  | Title: | Chief Executive Officer |

---

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

---

| |
|:---|
| **[Stockholder]** |
| Address: |
| Email: |

---

**SCHEDULE I**

**Stockholder Subject Shares**

[*See attached*]

**COGNOS STOCKHOLDER SHARES**

● [__]

**SCHEDULE II**

**Investor Rights Agreement Signatories**

[*See attached*]

**Investor Rights Agreement Signatories**

● [__]

**SCHEDULE III**

**Lock-up Agreement Signatories**

[*See attached*]

**Lock-up Agreement Signatories**

● [__]